Harbin Gloria Pharmaceuticals Co., Ltd.

Harbin Gloria Pharmaceuticals Co., Ltd. has seen a notable increase in its stock today, reaching an intraday high. The company has outperformed the China Shanghai Composite over the past month and year-to-date, despite facing longer-term challenges. Its market capitalization is CNY 5,619 million, with a solid Return on Equity.

Harbin Gloria Pharmaceuticals Co., Ltd. experienced notable stock activity, achieving a significant gain on July 1, 2026. Despite recent fluctuations, including a decline over the past month and year-to-date, the company maintains a mid-cap market capitalization and a return on equity of 15.80%.

Harbin Gloria Pharmaceuticals Co., Ltd. saw a notable increase in its stock today, contrasting with the broader market's modest gains. While the company has shown a positive trend over the past week, its long-term performance remains mixed, reflecting volatility and challenges within the pharmaceuticals sector.

Harbin Gloria Pharmaceuticals Co., Ltd. has recently experienced a valuation adjustment reflecting changes in its financial metrics. Key ratios, including P/E and price-to-book values, suggest a more favorable assessment, while long-term growth metrics indicate challenges, including declining net sales and low return on capital employed.

Harbin Gloria Pharmaceuticals Co., Ltd. saw a notable rise in stock performance on March 27, 2026, reaching an intraday high. Over the past year, the company has outperformed the China Shanghai Composite, despite facing long-term growth challenges. Recent quarters show positive momentum with increased net profit and improved cash flow.

Harbin Gloria Pharmaceuticals Co., Ltd. saw a notable decline in its stock today, contrasting with the broader market's performance. Despite recent short-term challenges, the company has shown resilience over the past year, with significant growth in net profit and a solid market capitalization.